Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PROTEST Trial - PROphylaxis for Venous ThromboEmbolism in Severe Traumatic Brain Injury, a Double-blind Randomized Controlled Trial

Trial Profile

PROTEST Trial - PROphylaxis for Venous ThromboEmbolism in Severe Traumatic Brain Injury, a Double-blind Randomized Controlled Trial

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dalteparin sodium (Primary)
  • Indications Venous thromboembolism
  • Focus Therapeutic Use
  • Acronyms PROTEST

Most Recent Events

  • 16 Nov 2022 Planned End Date changed from 1 Dec 2023 to 1 Dec 2027.
  • 16 Nov 2022 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2026.
  • 15 Feb 2019 Planned number of patients changed from 1500 to 1100.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top